Supriya Lifescience is a manufacturer of the active chemical ingredients that go into medicines - the part that actually treats the patient - built on a simple, stubborn idea: make everything yourself, from basic raw materials to the finished molecule, so you control the cost and the supply chain. Founded as a partnership in the mid-1980s and listed in 2021, the company has spent four decades deepening that backward integration, now producing up to nine chemical steps in-house and earning three-quarters of its revenue from products where it controls the chain from start to finish. That same do-it-yourself logic now explains its expansion from selling APIs to other drugmakers into making the finished pills and liquids itself, and into running long-term contract manufacturing for global pharmaceutical companies on their own molecules.
Business segments
A single engine with three deepening layers - an API manufacturing core that supplies over 1,500 customers globally, a contract manufacturing arm that locks in decade-long partnerships, and a finished-dose business that consumes its own ingredients - all built on the same backward-integrated factory floor.
1. API manufacturing: the molecule factory that supplies the world
The company makes 40-plus active pharmaceutical ingredients across five therapeutic areas, controlling up to nine chemical steps from raw material to finished molecule - which means it sets its own cost structure rather than buying expensive intermediates from someone else.
- Backward integration is the moat - 20 products are made from basic key starting materials in-house, contributing 76% of revenue, so the company is protected from price swings in the intermediate chemical market and from supply disruptions, particularly out of China.
- Dominant in niche molecules - it is the largest exporter from India by volume of chlorpheniramine maleate (45-50% share of Indian exports), ketamine hydrochloride (60-65%), and salbutamol sulphate (30-40%), where the combination of tricky chemistry and full backward integration keeps competition thin.
- A single mega-factory with five blocks - the Lote Parshuram site houses 932 kilolitres of reactor capacity across five regulatory-approved manufacturing blocks, the newest of which (Block E, commissioned in FY25) added 335 kilolitres and 33 reactors purpose-built for scaling innovative products.
- Regulatory approvals as a barrier to entry - the plant holds clearances from the USFDA (four inspections, most recently in 2026 with a voluntary-action-indicated classification), the European EDQM, Brazil's ANVISA, Japan's PMDA, and a dozen other agencies, meaning its products can be sold in virtually every regulated market on earth.
- R&D that feeds the pipeline - a team of 68 scientists at a government-approved R&D centre adds three to four new products a year and improves processes on existing ones, consistently investing about 5% of sales back into development.
2. Contract manufacturing (CDMO): a decade-long partner, not just a supplier
The company uses the same factory infrastructure and hazardous-chemistry expertise to manufacture APIs for innovator pharmaceutical companies under exclusive long-term contracts - turning a transactional supplier relationship into a sticky, multi-year partnership.
- A 10-year anchor contract - a landmark exclusive API supply agreement with a leading European company, expected to generate peak annual revenues of ₹40 crore starting in FY27, demonstrates the model: one deep relationship instead of many small orders.
- A dedicated facility away from the main plant - the Ambernath site, 60 kilometres from Nhava Sheva Port, was commercialised in 2026 as a dedicated CDMO hub with capabilities spanning complex API synthesis, tablets, capsules, liquids, nasal sprays, inhalers, and injectables.
- European companies are actively looking to shift manufacturing to India - the company reports rising interest from European pharmaceutical firms wanting to move their supply base, and it is in discussions with international brands for additional contract manufacturing partnerships.
- Full-service from lab to dossier - the CDMO engine provides process development, validation, stability testing, and regulatory dossier compilation, with a dedicated technology-transfer team and a newly added kilo-lab for high-value small-molecule APIs.
3. Finished dosage forms: eating its own cooking
The company has started making the actual pills, capsules, inhalers, and injectables - not just the active ingredient inside them - so it captures more of the value chain and uses its own APIs as raw material.
- Five manufacturing lines already running - the finished-dose operation produces tablets, capsules, liquids, nasal and inhalation products, injectables, and large-volume liquid fills, with thirty products under development and five exhibit batches completed.
- A novel patent-protected tablet - the R&D team has developed and patented a new tablet formulation of Semaglutide (the GLP-1 diabetes and weight-loss molecule), giving it a differentiated entry into one of the world's fastest-growing therapeutic categories.
- Go-to-market through partners - for less regulated markets, the company plans to sell through arrangements with larger pharmaceutical companies that already have distribution networks, while building toward its own ANDA filings for regulated markets like the US.
Group structure and partners
A single listed entity with no subsidiaries - the entire operation, from API synthesis to finished-dose manufacturing, sits inside one public company controlled by the founding family.
- The company is listed on the BSE and NSE under scrip code 543434, with no disclosed subsidiaries, joint ventures, or equity stakes in other operating entities.
- Executive leadership combines the founding family's technical depth - Dr. Satish Wagh (Chairman & MD), Dr. Saloni Wagh (Whole-time Director, PhD in Chemistry), and Shivani Wagh (Whole-time Director, MSc International Business) - with a professional CFO, Krishna Raghunathan, who previously held senior roles at Dr. Reddy's Laboratories and Granules India.
- Strategic academic partnerships with the Institute of Chemical Technology (ICT) in Mumbai and the Kalinga Institute of Industrial Technology (KIIT) support the R&D pipeline.